康弘药业：产品“布瑞哌唑片”取得注册证

Group 1 - The core point of the article is that Kanghong Pharmaceutical has received a drug registration certificate for Brexpiprazole tablets from the National Medical Products Administration, which is a significant regulatory approval for the company [1] - As of December 25, 2023, Kanghong Pharmaceutical's revenue composition for the first half of 2025 is reported to be 99.97% from the pharmaceutical manufacturing industry and 0.03% from other businesses [1] - The current market capitalization of Kanghong Pharmaceutical is 28.7 billion yuan [2]